Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical-stage company developing next-generation therapeutic vaccines and other immunotherapy treatments for cancer and chronic infectious diseases. Bellicum's novel approach leverages precise knowledge of signaling pathways that regulate immune responses to target specific factors capable of influencing the potency and duration of such responses. Our lead product, BP-GMAX-CD1, is currently in Phase I clinical trials.